Conquering Disease through Innovative Metabolomic Technology

About Us

We are a preclinical biopharmaceutical company harnessing innovative metabolomic technology to discover and develop life-saving therapies for patients. Metaba was originally founded to develop a promising adjunctive therapeutic for treatment of Tuberculosis (TB). Through collaborations and successful pilot projects with leading global pharmaceutical companies and research institutions, we have expanded our R&D efforts to additional indications, including Covid-19, Nontuberculosis Mycobacteria (NTM), Atherosclerosis, Nonalcoholic Steatohepatitis (NASH), and Idiopathic Pulmonary Fibrosis (IPF). The ability of Metaba to adapt quickly to other indications is enabled by our advanced metabolomics analysis platform combined with computer aided drug discovery methodologies, underscoring our dedication to delivering innovative therapies to improve patient outcomes.

Our Mission

Our mission is to become a leader in biopharmaceutical innovation by transforming our understanding of biological systems and developing innovative therapies using our cutting-edge metabolomic technology. We leverage the versatility of our platform to expand our impact to include other serious human diseases and target additional market opportunities.